About DENARASE® High Salt
How it works
DENARASE® High Salt is an engineered version of the wild-type Serratia marcescens endonuclease, which is commonly used for DNA removal applications in bioprocessing. Compared to the wild-type DENARASE® a few amino acids were substituted to provide the enzyme with an improved salt tolerance without losing its specificity for nucleic acids. DENARASE® High Salt shows higher activity over a wider range of salt concentrations and pH levels and so offers greater flexibility in bioprocessing.
Because of the great similarities to the wild-type enzyme, DENARASE® High Salt can be detected using the same Serratia marcescens endonuclease ELISA Kits, such as DENARASE® ELISA Kit.
Production of DENARASE® High Salt
DENARASE® High Salt is produced using our established, proprietary DENARASE® manufacturing process which is based on the expression in a gram-positive Bacillus sp. strain. The enzyme is produced under ISO 9001 standard, without the use of antibiotics and raw materials of animal origin or TSE/BSE risk.
DENARASE® - Best performance from low to high salt!
![Relative DNA clearance compared to others Relative DNA clearance compared to others](https://denarase.c-lecta.com/hs-fs/hubfs/Relative%20DNA%20clearance%20compared%20to%20others.png?width=2000&height=1439&name=Relative%20DNA%20clearance%20compared%20to%20others.png)
-
Peak performance at low & physiological salt concentrations
-
Use of DENARASE® below 200 mM salt
-
Designed to retain activity at elevated salt concentrations
- Highest activity over the broadest spectrum of salt concentrations
-
Use of DENARASE® High Salt above 200 mM
Order & test DENARASE® High Salt now!
- R&D-grade
Products for use in research and development
Intended for use in research and development applications and process development of biologicals such as viral vectors and vaccines. DENARASE® High Salt cleaves all forms of DNA and RNA and enables a simpler, more efficient harvest process at salt concentrations above 200 mM.Purity: ≥ 99%
Activity: > 250 U/µl
Formulation: Buffered aqueous glycerol solution
Storage Temperature: -20°C
Estimated Delivery time: 1-2 weeks (depending on region)- Produced in conformity under ISO 9001 standard
- Manufactured without the use of antibiotics, Triton X-100 and raw materials of animal origin
- Net price excluding VAT and shipment costs
Choose your size for DENARASE® High Salt:
- GMP-grade
DENARASE® High Salt GMP for biopharmaceutical manufacturing
The launch of the DENARASE® High Salt GMP grade for use in commercial manufacturing processes of biologicals is scheduled for Q2 2025.
- The manufacturing process of the High Salt GMP-grade will comply with the same regulations and standards as our well-known wild-type GMP-grade DENARASE® products.
- Produced under EU GMP conditions.
- Manufacturing free of animal-derived raw materials, Triton X-100 and antibiotics
- From a technical performance perspective, DENARASE® High Salt R&D- and GMP-grade will be equal.
The launch of the GMP grade DENARASE® High Salt is projected to be in Q2 2025.
- The manufacturing process of the High Salt GMP-grade will comply with the same regulations and standards as our well-known wild-type GMP-grade DENARASE® products.
- Free Sample
Products for use in research and development
Activity: > 250 U/µl
Formulation: Buffered aqueous glycerol solution
Storage Temperature: -20°C
Estimated Delivery time: 1-2 weeks (depending on region)
- Produced in conformity under ISO 9001 standard
- Manufactured without the use of antibiotics, Triton X-100 and raw materials of animal origin
- Net price excluding VAT and shipment costs
![DENARASE_High Salt_Group](https://denarase.c-lecta.com/hs-fs/hubfs/DENARASE_High%20Salt_Group.png?width=2000&name=DENARASE_High%20Salt_Group.png)
DENARASE® High Salt GMP for biopharmaceutical manufacturing
The launch of the DENARASE® High Salt GMP grade for use in commercial manufacturing processes of biologicals is scheduled for Q2 2025.
- The manufacturing process of the High Salt GMP-grade will comply with the same regulations and standards as our well-known wild-type GMP-grade DENARASE® products.
- Produced under EU GMP conditions.
- Manufacturing free of animal-derived raw materials, Triton X-100 and antibiotics
- From a technical performance perspective, DENARASE® High Salt R&D- and GMP-grade will be equal.
![GMP Coming soon-3](https://denarase.c-lecta.com/hs-fs/hubfs/GMP%20Coming%20soon-3.png?width=576&height=405&name=GMP%20Coming%20soon-3.png)
The launch of the GMP grade DENARASE® High Salt is projected to be in Q2 2025.
Ready to elevate your Viral Vector Bioprocessing?
![DENARASE® expert team](https://denarase.c-lecta.com/hs-fs/hubfs/Unbenannt-1-1.jpg?width=1200&height=800&name=Unbenannt-1-1.jpg)
DENARASE® - Your complete toolkit for DNA removal
Pick the most efficient DENARASE® version for your application.
![c-LEcta-DENARASE-ELISA-Kit](https://denarase.c-lecta.com/hs-fs/hubfs/c-LEcta-DENARASE-ELISA-Kit.jpg?width=1200&height=800&name=c-LEcta-DENARASE-ELISA-Kit.jpg)
The One-for-all Serratia marcescens ELISA Kit!
For the quantification of residual Serratia marcescens endonucleases including DENARASE® High Salt.
Development of DENARASE®
2024
Launch of DENARASE® High Salt
c-LEcta launched DENARASE® High Salt, an engineered version of its top-selling product DENARASE®.
The newest addition to the DENARASE® portfolio has been especially designed to retain activity at higher salt concentrations and a broad pH spectrum. These features provide customers with greater process flexibility and increased cost efficiency in viral vector manufacturing processes that benefit from elevated salt levels.
![highsalt_Gruppe](https://denarase.c-lecta.com/hs-fs/hubfs/highsalt_Gruppe.jpg?width=2000&height=2000&name=highsalt_Gruppe.jpg)
2023
New sizes of R&D-grade DENARASE® available
c-LEcta has just launched additional sizes of DENARASE® for research and development use.
Being widely applied in biopharmaceutical R&D and manufacturing, DENARASE sizes of 1 MU and 5 MU will now also be available as R&D-grade, in addition to GMP-grade.
![R&D](https://denarase.c-lecta.com/hs-fs/hubfs/R%26D.jpg?width=1000&height=1000&name=R%26D.jpg)
2022
Global application of DENARASE® and ELISA Kit in biopharmaceutical manufacturing
DENARASE® and ELISA Kit are established highest-quality products, applied in the manufacturing of viral vectors for Gene therapies and vaccines:
> 150 customers in > 30 countries
DENARASE® is applied in 4 Commercial and 40+ Clinical Phase I-III viral vector manufacturing processes
![AdobeStock_335262300_Preview-1](https://denarase.c-lecta.com/hs-fs/hubfs/AdobeStock_335262300_Preview-1.jpg?width=1000&height=1000&name=AdobeStock_335262300_Preview-1.jpg)
2021
Drug Master File for DENARASE® accepted by FDA
Dedicated regulatory support for US-market approvals of pharmaceutical products via own US FDA Drug Master File.
In addition, certified compliance with the EXCiPACT and ANSI NSF 363 Standard (meeting GMP for pharmaceutical excipients)
![EXCIPACT-Collage](https://denarase.c-lecta.com/hs-fs/hubfs/EXCIPACT-Collage.jpg?width=1000&height=1000&name=EXCIPACT-Collage.jpg)
2020
COVID-Support
Focused support for customers developing and manufacturing COVID-19 vaccines at unprecedented speed
Concerted efforts of c-LEcta teams with COVID-19 vaccine customers succeeded in the delivery of large, unplanned quantities of DENARASE on short timelines
c-LEcta’s resilient manufacturing and distribution network kept COVID-19 related supply issues to general customers at an absolute minimum
![c-LEcta-covid-vaccine-1](https://denarase.c-lecta.com/hs-fs/hubfs/c-LEcta-covid-vaccine-1.jpg?width=1000&height=1000&name=c-LEcta-covid-vaccine-1.jpg)
2020
Launch of DENARASE® ELISA Kit
Launch of own ELISA kit for the detection of S. marcescens endonucleases in process-derived samples
Fastest and most sensitive ELISA kit available on the market
![ELISA-Kit_1000x1000](https://denarase.c-lecta.com/hs-fs/hubfs/ELISA-Kit_1000x1000.jpg?width=1000&height=1000&name=ELISA-Kit_1000x1000.jpg)
2017
First DENARASE®-related patents granted
Patents were successfully granted for the production technology of DENARASE® based on recombinant expression in Bacillus
![DENARASE-Patent-USA](https://denarase.c-lecta.com/hs-fs/hubfs/DENARASE-Patent-USA.jpg?width=1000&height=1000&name=DENARASE-Patent-USA.jpg)
2012
Product launch of DENARASE®
DENARASE® fulfills highest quality standards for biopharmaceutical manufacturing
Starting to build a global sales and distribution network for life science customers
Growth of internal quality, production, distribution and sales functions
![DENARASE_1000x1000](https://denarase.c-lecta.com/hs-fs/hubfs/DENARASE_1000x1000.jpg?width=1000&height=1000&name=DENARASE_1000x1000.jpg)
2012
Manufacturing of DENARASE® under GMP conditions
Requirements of the biopharmaceutical industry for a GMP product were identified
Partnering with a contract manufacturing organization (CMO) to produce DENARASE® under EU GMP conditions
Manufacturing process free of animal derived raw materials and antibiotics was established
![Production_1000x1000](https://denarase.c-lecta.com/hs-fs/hubfs/Production_1000x1000.jpg?width=1000&height=1000&name=Production_1000x1000.jpg)
2009-2012
Start of DENARASE® project: Strain selection, development of upstream and purification process
Project started: Application of endonucleases for DNA removal during protein purification
c-LEcta‘s Bacillus strain, an endotoxin-free expression host, yielded highly active DENARASE product. Purity of ≥99 % was achieved after purification.
![Fermenter_1000x1000](https://denarase.c-lecta.com/hs-fs/hubfs/Fermenter_1000x1000.jpg?width=1000&height=1000&name=Fermenter_1000x1000.jpg)
Get in touch with our DENARASE® expert team!
![Vaishnavi Devarakonda](https://denarase.c-lecta.com/hubfs/Vaishnavi%20Devarakonda.jpg)
Vaishnavi Devarakonda
DENARASE® Sales
![Melissa Rangel](https://denarase.c-lecta.com/hubfs/Melissa%20Rangel.jpg)
Melissa Rangel
DENARASE® Sales
Need support? Contact me!
![Cynthia Hofmann-Orsetti](https://denarase.c-lecta.com/hubfs/Cynthia%20Hofmann-Orsetti.jpg)
Cynthia Hofmann-Orsetti
DENARASE® Sales
Need support? Contact me!